Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1

Leukemia Research

Volumn 38, Issue 3, 2014, Pages 361-370

  Tomita, Osamu ^a,b   Iijima, Kazutoshi ^a,c   Ishibashi, Takeshi ^a,b   Osumi, Tomoo ^d   Kobayashi, Kenichiro ^a   Okita, Hajime ^a   Saito, Masahiro ^e   Mori, Tetsuya ^d   Shimizu, Toshiaki ^e   Kiyokawa, Nobutaka ^a  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute lymphoblastic leukemia; BCR ABL1; Phosphorylation; SNX2 ABL1; Tyrosine kinase inhibitor

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; BCR-ABL1; PHOSPHORYLATION; SNX2-ABL1; TYROSINE KINASE INHIBITOR;

ANIMALS; B-LYMPHOCYTES; BENZAMIDES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC VECTORS; HUMANS; INTERLEUKIN-3; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES; RETROVIRIDAE; SORTING NEXINS; THIAZOLES; TRANSFECTION;

EID: 84894265023     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.11.017     Document Type: Article

References (52)

1. Harrison C.J., Moorman A.V., Barber K.E., Broadfield Z.J., Cheung K.L., Harris R.L., et al. Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. Br J Haematol 2005, 129:520-530.
2. Pui C.-H., Mullighan C.G., Evans W.E., Relling M.V. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there. Blood 2012, 120:1165-1174.
3. Suryanarayan K., Hunger S.P., Kohler S., Carroll A.J., Crist W., Link M.P., et al. Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias. Blood 1991, 77:324-330.
4. De Braekeleer E., Douet-Guilbert N., Rowe D., Bown N., Morel F., Berthou C., et al. ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol 2011, 86:361-371.
5. Greuber E.K., Smith-Pearson P., Wang J., Pendergast A.M. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 2013, 13:559-571.
6. Warmuth M., Danhauser-Riedl S., Hallek M. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Ann Hematol 1999, 78:49-64.
7. Ribeiro R.C., Abromowitch M., Raimondi S.C., Murphy S.B., Behm F., Williams D.L. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 1987, 70:948-953.
8. Schultz K.R., Pullen D.J., Sather H.N., Shuster J.J., Devidas M., Borowitz M.J., et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007, 109:926-935.
9. Schultz K.R., Bowman W.P., Aledo A., Slayton W.B., Sather H., Devidas M., et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009, 27:5175-5181.
10. Rives S., Estella J., Gómez P., López-Duarte M., de Miguel P.G., Verdeguer A., et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol 2011, 154:600-611.
11. Jain P., Kantarjian H., Cortes J. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol 2013, 14:127-143.
12. Wassmann B., Pfeifer H., Goekbuget N., Beelen D.W., Beck J., Stelljes M., et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006, 108:1469-1477.
13. Liu-Dumlao T., Kantarjian H., Thomas D.A., O'Brien S., Ravandi F. Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep 2012, 14:387-394.
14. Fielding A.K. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 2010, 95:8-12.
15. Weisberg E., Manley P.W., Cowan-Jacob S.W., Hochhaus A., Griffin J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007, 7:345-356.
16. Olivieri A., Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol 2007, 18(Suppl. 6):vi42-vi46.
17. Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
18. Foà R., Vitale A., Vignetti M., Meloni G., Guarini A., De Propris M.S., et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011, 118:6521-6528.
19. Deguchi Y., Kimura S., Ashihara E., Niwa T., Hodohara K., Fujiyama Y., et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 2008, 32:980-983.
20. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukaemia. N Engl J Med 2010, 362:2251-2259.
21. Niwa T., Asaki T., Kimura S. NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. Anal Chem Insights 2007, 2:93-106.
22. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
23. Eide C.A., Adrian L.T., Tyner J.W., Mac Partlin M., Anderson D.J., Wise S.C., et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res 2011, 71:3189-3195.
24. Chan W.W., Wise S.C., Kaufman M.D., Ahn Y.M., Ensinger C.L., Haack T., et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 2011, 19:556-568.
25. Saglio G. Second-generation TKIs: which and when. Leukemia Suppl 2012, 1:S40-S42.
26. Ernst T., Score J., Deininger M., Hidalgo-Curtis C., Lackie P., Ershler W.B., et al. Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia. Br J Haematol 2011, 153:43-46.
27. Van Limbergen H., Beverloo H.B., van Drunen E., Janssens A., Hählen K., Poppe B., et al. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer 2001, 30:274-282.
28. Graux C., Cools J., Melotte C., Quentmeier H., Ferrando A., Levine R., et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36:1084-1089.
29. De Keersmaecker K., Graux C., Odero M.D., Mentens N., Somers R., Maertens J., et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 2005, 105:4849-4852.
30. Hidalgo-Curtis C., Chase A., Drachenberg M., Roberts M.W., Finkelstein J.Z., Mould S., et al. The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1. Genes Chromosomes Cancer 2008, 47:379-385.
31. Mustjoki S., Hernesniemi S., Rauhala A., Kähkönen M., Almqvist A., Lundán T., et al. A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica 2009, 94:1469-1471.
32. Inokuchi K., Wakita S., Hirakawa T., Tamai H., Yokose N., Yamaguchi H., et al. B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations. Int J Hematol 2011, 94:255-260.
33. Roberts K.G., Morin R.D., Zhang J., Hirst M., Zhao Y., Su X., et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012, 22:153-166.
34. Worby C.A., Dixon J.E. Sorting out the cellular functions of sorting nexins. Nat Rev Mol Cell Biol 2002, 3:919-931.
35. Carlton J., Bujny M., Rutherford A., Cullen P. Sorting nexins-unifying trends and new perspectives. Traffic 2005, 6:75-82.
36. Ogi S., Fujita H., Kashihara M., Yamamoto C., Sonoda K., Okamoto I., et al. Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs. Cancer Sci 2013, 104:573-583.
37. Masuzawa A., Kiyotani C., Osumi T., Shioda Y., Iijima K., Tomita O., et al. Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript. Eur J Haematol 2013, [Epub ahead of print].
38. Iijima K., Yamada H., Miharu M., Imadome K., Miyagawa Y., Akimoto S., et al. ZNF385B is characteristically expressed in germinal center B cells and involved in B-cell apoptosis. Eur J Immunol 2012, 42:3405-3415.
39. Yamada H., Iijima K., Tomita O., Taguchi T., Miharu M., Kobayashi K., et al. Effects of insulin-like growth factor-1 on B-cell precursor acute lymphoblastic leukemia. Int J Hematol 2013, 97:73-82.
40. Kiyokawa N., Lee E.K., Karunagaran D., Lin S.-Y., Hung M.-C. Mitosis-specific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor. J Biol Chem 1997, 272:18656-18665.
41. Barilá D., Superti-Furga G. An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet 1998, 18:280-282.
42. Chen S., O'Reilly L.P., Smithgall T.E., Engen J.R. Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core. J Mol Biol 2008, 383:414-423.
43. Stanglmaier M., Warmuth M., Kleinlein I., Reis S., Hallek M. The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia 2003, 17:283-289.
44. Warmuth M., Bergmann M., Priess A., Häuslmann K., Emmerich B., Hallek M. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem 1997, 272:33260-33270.
45. Meyn M.A., Wilson M.B., Abdi F.A., Fahey N., Schiavone A.P., Wu J., et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006, 281:30907-30916.
46. Soverini S., Colarossi S., Gnani A., Castagnetti F., Rosti G., Bosi C., et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007, 92:401-404.
47. Thomas J., Wang L., Clark R.E., Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104:3739-3745.
48. Bixby D., Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 2009, 46:1-7. 6.
49. Li S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 2008, 49:19-26.
50. Hantschel O., Rix U., Schmidt U., Bürckstümmer T., Kneidinger M., Schütze G., et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007, 104:13283-13288.
51. Vajpai N., Strauss A., Fendrich G., Cowan-Jacob S.W., Manley P.W., Grzesiek S., et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 2008, 283:18292-18302.
52. Hantschel O. Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer 2012, 3:436-446.